 |
About Rigel:
- Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.
- Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms.
- Rigel’s productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates.
- Current product development programs include fostamatinib (previously R788), an oral syk inhibitor that is in its phase 3 clinical trial program (OSKIRA) for rheumatoid arthritis (w/partner AstraZeneca); R343, an inhaled syk inhibitor for asthma and R333, a topical JAK/SYK inhibitor for discoid lupus - both of which have commenced Phase 2 clinical trials; and R348, a topical JAK/SYK inhibitor in a Phase 1 clinical trial for the treatment of chronic dry eye.
 |
|
senior management
